2 février 2022
We are advising Nuclera, the pioneer in making biology accessible to everyone through desktop bioprinting, on its Series B financing, which raised a $42.5 million first close. The Series B caps off a landmark year for Nuclera in which it also completed the transformational acquisition of E Ink's digital microfluidics, and we are proud to have supported the company throughout this journey.
Nuclera’s ground-breaking protein printing technology has attracted many new and existing institutional and strategic investors in this financing round including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, the Future Fund, and G. K. Goh. The funds raised will be used to accelerate the development and commercialisation of its eProtein™ desktop bioprinter.
Nuclera’s eProtein™ desktop bioprinter is a breakthrough rapid protein prototyping and discovery platform that enables protein printing in just 24 hours, many orders of magnitude faster than existing methods of protein synthesis. The eProtein bioprinter is powered by the company’s eDrop™ digital microfluidic technology - a core enabling technology borne out of the company’s strategic partnership with E Ink.
The eProtein desktop bioprinter will initially screen and print proteins for research and drug discovery customers, and the funding will also fast-track the company’s march towards developing an all-encompassing proteomics platform. The all-in-one platform will increase scientific reproducibility, accelerate drug discovery, and contribute to the ever-expanding bio-economy.
Commenting on the transaction, corporate partner Ross McNaughton said: "We are delighted to continue our support of Michael and the Nuclera team by advising on this tremendous funding round. Nuclera is right at the cutting edge of synthetic biology, and rapid prototyping made possible by its eProtein bioprinter is set to have a revolutionary impact. It is another great example of the world-leading innovation coming out of the Cambridge ecosystem and we look forward to continuing our close relationship as the business continues on its incredible trajectory."
Co-founder and CEO of Nuclera, Dr Michael Chen, added: “Our eProtein desktop bioprinter makes it easy for scientists to access the proteins they need in a single day rather than the weeks, months, or even years it currently takes. The new financing and partners we are announcing today is a strong vote of confidence in our mission to increase the accessibility of the drug discovery and bioinnovation process. Ross, Adrian and the Taylor Wessing team have once again provided us with outstanding support in advising on this fundraise. Their sector knowledge and expertise are unparalleled and the insightful, commercial guidance they have provided throughout Nuclera's transformational year have been invaluable to us."
The team was led by partners Ross McNaughton and Adrian Toutoungi with support from associates Charlie Adams and Oli Denne.
par plusieurs auteurs